$25.07 Million in Sales Expected for Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) This Quarter

Brokerages forecast that Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) will announce sales of $25.07 million for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Adamas Pharmaceuticals’ earnings. The highest sales estimate is $26.50 million and the lowest is $23.25 million. Adamas Pharmaceuticals posted sales of $20.18 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 24.2%. The company is scheduled to announce its next quarterly earnings results on Thursday, November 4th.

According to Zacks, analysts expect that Adamas Pharmaceuticals will report full-year sales of $94.43 million for the current financial year, with estimates ranging from $90.28 million to $98.60 million. For the next year, analysts expect that the firm will report sales of $126.17 million, with estimates ranging from $112.10 million to $144.03 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Adamas Pharmaceuticals.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings data on Sunday, August 8th. The specialty pharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.02.

A number of analysts have recently weighed in on the stock. William Blair reaffirmed a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Friday, August 27th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Adamas Pharmaceuticals in a research report on Tuesday, August 10th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $8.56.

Shares of Adamas Pharmaceuticals stock opened at $4.55 on Wednesday. The company has a current ratio of 5.30, a quick ratio of 4.94 and a debt-to-equity ratio of 21.25. The company’s fifty day simple moving average is $4.80 and its two-hundred day simple moving average is $5.05. The company has a market cap of $207.46 million, a P/E ratio of -2.69 and a beta of 2.69. Adamas Pharmaceuticals has a 12-month low of $2.96 and a 12-month high of $9.15.

In related news, insider Vijay Shreedhar sold 6,200 shares of the company’s stock in a transaction dated Monday, June 21st. The shares were sold at an average price of $5.16, for a total value of $31,992.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 18.90% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. The PNC Financial Services Group Inc. boosted its stake in Adamas Pharmaceuticals by 42.9% in the 1st quarter. The PNC Financial Services Group Inc. now owns 10,000 shares of the specialty pharmaceutical company’s stock worth $48,000 after purchasing an additional 3,000 shares in the last quarter. HighTower Advisors LLC bought a new position in Adamas Pharmaceuticals in the 2nd quarter worth about $66,000. Cubist Systematic Strategies LLC bought a new position in Adamas Pharmaceuticals in the 2nd quarter worth about $76,000. Walleye Capital LLC bought a new position in Adamas Pharmaceuticals during the 1st quarter valued at about $80,000. Finally, XTX Topco Ltd bought a new position in Adamas Pharmaceuticals during the 2nd quarter valued at about $86,000. Institutional investors own 71.69% of the company’s stock.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy.

Read More: What is a Reverse Stock Split?

Get a free copy of the Zacks research report on Adamas Pharmaceuticals (ADMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.